172 related articles for article (PubMed ID: 28490781)
1. Identification of Long Noncoding RNAs Deregulated in Papillary Thyroid Cancer and Correlated with BRAF
Goedert L; Plaça JR; Fuziwara CS; Machado MCR; Plaça DR; Almeida PP; Sanches TP; Santos JFD; Corveloni AC; Pereira IEG; de Castro MM; Kimura ET; Silva WA; Espreafico EM
Sci Rep; 2017 May; 7(1):1662. PubMed ID: 28490781
[TBL] [Abstract][Full Text] [Related]
2. Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.
Wang Q; Yang H; Wu L; Yao J; Meng X; Jiang H; Xiao C; Wu F
Thyroid; 2016 Dec; 26(12):1719-1732. PubMed ID: 27758138
[TBL] [Abstract][Full Text] [Related]
3. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
[TBL] [Abstract][Full Text] [Related]
5. Key candidate genes associated with BRAF
Yu X; Zhong P; Han Y; Huang Q; Wang J; Jia C; Lv Z
J Cell Physiol; 2019 Dec; 234(12):23369-23378. PubMed ID: 31161615
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic Properties of the Antisense lncRNA
Esposito R; Esposito D; Pallante P; Fusco A; Ciccodicola A; Costa V
Cancer Res; 2019 May; 79(9):2124-2135. PubMed ID: 30862713
[No Abstract] [Full Text] [Related]
7. Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene.
Li T; Yang XD; Ye CX; Shen ZL; Yang Y; Wang B; Guo P; Gao ZD; Ye YJ; Jiang KW; Wang S
Cell Cycle; 2017 Jan; 16(2):224-231. PubMed ID: 27929737
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of long noncoding RNAs in human papillary thyroid carcinoma.
Cao Y; Shi C; Li J; Liang Y; Qiu J; Yuan L; Yong Z; Zhang DX; Shi GQ
Neoplasma; 2019 Mar; 66(2):245-251. PubMed ID: 30569720
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma.
Lan X; Zhang H; Wang Z; Dong W; Sun W; Shao L; Zhang T; Zhang D
Gene; 2015 Sep; 569(1):109-17. PubMed ID: 26003293
[TBL] [Abstract][Full Text] [Related]
10. Low-Density Lipoprotein Receptor Is a Key Driver of Aggressiveness in Thyroid Tumor Cells.
Revilla G; Ruiz-Auladell L; Vallverdú NF; Santamaría P; Moral A; Pérez JI; Li C; Fuste V; Lerma E; Corcoy R; Pitoia F; Escolà-Gil JC; Mato E
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446330
[TBL] [Abstract][Full Text] [Related]
11. BRAF-Activated Long Noncoding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor.
Zheng H; Wang M; Jiang L; Chu H; Hu J; Ning J; Li B; Wang D; Xu J
Cancer Res Treat; 2016 Apr; 48(2):698-707. PubMed ID: 26323637
[TBL] [Abstract][Full Text] [Related]
12. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
13. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
14. The gene expression of GPER1 is low in fresh samples of papillary thyroid carcinoma (PTC), and in silico analysis.
Bertoni APS; Manfroi PA; Tomedi J; Assis-Brasil BM; de Souza Meyer EL; Furlanetto TW
Mol Cell Endocrinol; 2021 Sep; 535():111397. PubMed ID: 34273443
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of novel long intergenic non‑coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer.
Tan J; Liu L; Zuo Z; Song B; Cai T; Ding D; Lu Y; Ye X
Oncol Rep; 2020 Oct; 44(4):1489-1501. PubMed ID: 32945494
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA LINC00313 modulates papillary thyroid cancer tumorigenesis via sponging miR-4429.
Wu WJ; Yin H; Hu JJ; Wei XZ
Neoplasma; 2018 Nov; 65(6):933-942. PubMed ID: 29940766
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
Liu D; Liu Z; Condouris S; Xing M
J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
[TBL] [Abstract][Full Text] [Related]
19. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
